Compare ATRA & STSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRA | STSS |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.1M | 83.3M |
| IPO Year | 2014 | 2022 |
| Metric | ATRA | STSS |
|---|---|---|
| Price | $15.69 | $2.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | 63.1K | ★ 176.2K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | ★ $151,930,000.00 | $306,344.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.98 | ★ N/A |
| Revenue Growth | ★ 51.27 | N/A |
| 52 Week Low | $5.01 | $2.28 |
| 52 Week High | $18.71 | $690.01 |
| Indicator | ATRA | STSS |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 38.51 |
| Support Level | $12.05 | $2.28 |
| Resistance Level | $15.12 | $3.23 |
| Average True Range (ATR) | 1.08 | 0.29 |
| MACD | 0.20 | 0.06 |
| Stochastic Oscillator | 93.44 | 51.33 |
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.